Key facts
- It has raised $17.1M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Y Combinator, Andreessen Horowitz, Mana Ventures, Global Brain, Gaingels — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for FidoCure
- ·The full record, as it builds
Funding rounds
No funding rounds for FidoCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FidoCure
Developer of an AI-driven precision medicine platform designed for canine cancer treatment. The company leverages next-generation sequencing and clinical data to analyze naturally occurring canine cancers, maintaining a proprietary database for cancer analysis and provides genomic sequencing services and targeted therapy recommendations for dogs with cancer to deliver precision medicine solutions that improve treatment outcomes, enabling veterinarians to deliver personalized treatment plans that address the unique characteristics of each dog's cancer.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2016
- Employees
- 22
- Website
- fidocure.com/
- Ownership
- Privately Held (backing)
FidoCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FidoCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FidoCure in its N-PORT filings yet. We sweep new filings monthly.